Edesa Biotech, Inc.
We are a clinical-stage biopharmaceutical company exploring new ways to treat inflammatory and immune-related diseases.
Our goal is to transform the lives of patients
suffering from acute and chronic diseases
First in Class mAbs
Edesa’s monoclonal antibody candidates have been developed as host-directed therapeutics targeting immune dysregulation
Broad Potential Utility
Our drug candidates are designed to modulate pathways that are implicated across multiple immune-related diseases
Edesa is a Recipient of a Federal Strategic Innovation Fund Grant Award
New Hope from a Government-Funded Phase 2 Study
Acute Respiratory Distress Syndrome (ARDS)
Life-Threatening Respiratory Failure
- 10% of all admissions to Intensive Care Units (ICU)
- 40% Mortality in the ICU
Frequent Causes
- Viral infections like influenza and Covid-19, bacteria, smoke/chemical inhalation and traumatic injury
Promising Clinical Results
- 84% mortality reduction in critically ill patients. Learn more
Fast Tracked in the U.S.
- Potential to address an unmet medical need.